# US 10,478,455 B2 · Therapeutic use of tetrathiomolybdate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,478,455 B2
- Document ID: US10478455B2
- Status: Granted
- Kind: B2
- Application number: 13/630,180
- Filed: 2012-09-28
- Published: 2013-07-11
- Granted: 2019-11-19
- Earliest claimed: 2010-03-30
- Assignees: UCL Business PLC
- Applicants: Ucl Business Ltd
- Inventors: Mervyn Singer; John Francis Martin; Alex Peter Dyson
- Web page: https://patentgrep.com/patent/US10478455B2

## CPC

- A61K 33/02: Ammonia; Compounds thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Tetrathiomolybdate is for use in therapy of a condition requiring reduced metabolism of an organ or whole body, e.g. myocardial infection, stroke or ischaemia-reperfusion injury.

## Claims

### Claim 1

A method for acute treatment of ischemia-reperfusion injury (IRI) in a subject that has undergone ischemic injury and is now at risk for acute injury caused by reperfusion following said ischemic injury, wherein said method comprises administering, to said subject, tetrathiomolybdate (TTM), via continuous infusion, wherein a total dose of up to 20 mg/kg TTM is administered to the subject over a period of one hour or less, such that within two hours of initiating treatment with TTM, there occurs in the subject a decrease in at least one of oxygen consumption and carbon dioxide production, thereby providing acute treatment of said IRI.

### Claim 2 (depends on 1)

The method, according to claim 1, wherein the injury is of a head.

### Claim 3 (depends on 1)

The method, according to claim 1, wherein the injury is of a brain.

### Claim 4 (depends on 1)

The method, according to claim 1, wherein the treatment is for stroke.

### Claim 5 (depends on 1)

The method, according to claim 1, wherein the injury is of a heart.

### Claim 6 (depends on 5)

The method, according to claim 5, wherein the subject is undergoing a procedure selected from coronary artery bypass surgery, open heart surgery and treatment for coronary artery thrombosis.

### Claim 7 (depends on 1)

The method, according to claim 1, wherein the injury is of a leg or kidney.

### Claim 8 (depends on 7)

The method, according to claim 7, wherein the subject is undergoing aortic cross-clamping for peripheral vascular surgery.

### Claim 9 (depends on 1)

The method, according to claim 1, wherein the treatment is for shock.

### Claim 10 (depends on 1)

The method, according to claim 1, wherein the treatment is for hypoxemia.

### Claim 11 (depends on 1)

The method, according to claim 1, wherein the treatment is for hemorrhage.

### Claim 12 (depends on 1)

The method, according to claim 1, wherein the treatment is for cardiac arrest.

### Claim 13 (depends on 1)

The method, according to claim 1, wherein the TTM is administered via intravenous administration.